

Shenzhen City Yaxin General Machinery Co., Ltd. Mot. at 1. Order No. 12 (Nov. 6, 2020), *unreviewed by* Notice (Nov. 24, 2020); *see* 85 FR 77239–40 (Dec. 1, 2020). The Commission terminated the investigation as to the following respondents based on consent orders and/or settlement agreements: Eddie Bauer LLC and PSEB Holdings, LLC; DHgate; Everich and Tomic Houseware Co., Ltd. Order No. 13 (Nov. 30, 2020), *unreviewed by* Notice (Dec. 21, 2020); Order No. 17 (Jan. 27, 2021), *unreviewed by* Notice (Feb. 16, 2021); Order No. 19 (Feb. 22, 2021), *unreviewed by* Notice (Mar. 12, 2021). The Commission also terminated the investigation with respect to the '282 trademark. Order No. 16 (Jan. 11, 2021), *unreviewed by* Notice (Feb. 8, 2021).

On April 14, 2021, the Commission found the Defaulting Respondents in default. Order No. 21 (Mar. 22, 2021), *unreviewed by* Notice (Apr. 14, 2021). The Commission also permitted Hydro Flask to withdraw the amended complaint as to the remaining respondents: HydroFlaskPup, Yiwu Honglu Daily Necessities Co., Ltd., and Yiwu Houju E-commerce Firm. Order No. 22 (Apr. 7, 2021), *unreviewed by* Notice (Apr. 22, 2021).

On April 8, 2021, Hydro Flask filed a motion for summary determination of a violation of section 337 pursuant to Commission Rules 210.16(c)(2), 210.18 (19 CFR 210.16(c)(2), 210.18) to support its request for entry of a GEO with respect to all asserted patents and trademarks. On August 9, 2021, OUII filed a response in support of the motion.

On September 3, 2021, the presiding chief administrative law judge ("CALJ") issued an initial determination ("ID") granting in part Hydro Flask's motion for summary determination. The ID finds that Hydro Flask has shown by reliable, probative, and substantial evidence that a violation of section 337 has occurred with respect to the '784, '365, and '888 trademarks, and the D'468, D'012, and D'320 patents, and that the domestic industry requirement is satisfied for the infringed trademarks and patents. The ID finds that a violation has been established with respect to ten out of thirteen defaulting respondents: Cangnan Kaiyisi E-Commerce Technology Co., Ltd.; Yongkang Huiyun Commodity Co., Ltd.; Wuyi Loncin Bottle Co., Ltd.; Zhejiang Yongkang Unique Industry & Trade Co., Ltd.; Suzhou Prime Gifts Co., Ltd.; Hangzhou Yuehua Technology Co., Ltd.; Guangzhou Yawen Technology Co., Ltd.; Jinhua City Ruizhi E-Commerce Co., Ltd.; Wo Ma Te (Tianjin) International Trade Co., Ltd.; and

Shenzhen City Yaxin General Machinery Co., Ltd. The ID also finds that no violation has been established as to respondents Shenzhen Huichengyuan Technology Co., Ltd.; Sinbada Impex Co., Ltd.; and Zhejiang Yuchuan Industry & Trade Co., Ltd.

The ID contains the CALJ's recommended determination on remedy and bonding ("RD"). The RD recommends issuance of a GEO with respect to the asserted patents and trademarks. The RD does not recommend issuance of any cease and desist orders. No petitions for review were filed.

The Commission determined to review the subject ID in part. *See* 86 FR 59424–26 (Oct. 27, 2021). Specifically, the Commission determined to review the ID's finding that Hydro Flask has satisfied the economic prong of the domestic industry requirement under section 337(a)(3)(A). *Id.*; *see* ID at 89–92. On review, the Commission affirmed the ID's finding that Hydro Flask has established a domestic industry under section 337(a)(3)(A). *Id.* The Commission also requested written submissions on remedy, the public interest, and bonding. *Id.*

On November 4, 2021, Complainants and OUII filed their opening written submissions on remedy, the public interest, and bonding. On November 12, 2021, OUII filed its responsive written submission. No other submissions were received by the Commission.

Having reviewed the submissions filed in response to the Commission request for briefing and the evidentiary record, the Commission has determined that the appropriate form of relief in this investigation is a GEO prohibiting the unlicensed importation of certain vacuum insulated flasks and components thereof that infringe the sole claims of the D'468, D'012, and D'320 patents and the '784, '365, and '888 trademarks.

The Commission has further determined that the public interest factors enumerated in subsection (d)(1) (19 U.S.C. 1337(d)(1)) do not preclude issuance of the above-referenced remedial order. Finally, the Commission has determined that a bond in the amount of one hundred (100) percent of the entered value is required to permit temporary importation of the articles in question during the period of Presidential review (19 U.S.C. 1337(j)). The investigation is terminated.

The Commission's order and the record upon which it based its determination were delivered to the President and to the United States Trade Representative on the day of their issuance. The Commission has also

notified the Secretary of the Treasury of the order.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and in part 210 of the Commission's Rules of Practice and Procedure, 19 CFR part 210.

The Commission vote for this determination took place on January 5, 2022.

By order of the Commission.

Issued: January 5, 2022.

**Lisa Barton,**

*Secretary to the Commission.*

[FR Doc. 2022–00281 Filed 1–10–22; 8:45 am]

**BILLING CODE 7020–02–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA–939]

#### Bulk Manufacturer of Controlled Substances Application: Curia Missouri Inc.

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Curia Missouri Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before March 14, 2022. Such persons may also file a written request for a hearing on the application on or before March 14, 2022.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on August 19, 2021, Curia Missouri Inc., 2460 West Bennett Street, Springfield, Missouri 65807, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid.	2010	I

Controlled substance	Drug code	Schedule
Amphetamine ...	1100	II
Lisdexamphetamine.	1205	II
Methylphenidate	1724	II
Phenylacetone ..	8501	II
Tapentadol .....	9780	II

The company plans to bulk manufacture the above-listed controlled substances in bulk for distribution to its customers. No other activities for these drug codes are authorized for this registration.

**Brian S. Besser,**

*Acting Assistant Administrator.*

[FR Doc. 2022-00325 Filed 1-10-22; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA-942]

**Bulk Manufacturer of Controlled Substances Application: Johnson Matthey, Inc.**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Johnson Matthey, Inc., has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before March 14, 2022. Such persons may also file a written request for a hearing on the application on or before March 14, 2022.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on November 2, 2021, Johnson Matthey, Inc., 2003 Nolte Drive West Deptford, New Jersey 08066-1742, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled Substance	Drug Code	Schedule
Gamma Hydroxybutyric Acid ..	2010	I
Marihuana .....	7360	I
Tetrahydrocannabinols .....	7370	I
Noroxymorphone .....	9145	I
Difenoxin .....	9168	I
Amphetamine .....	1100	II
Methamphetamine .....	1105	II
Lisdexamfetamine .....	1205	II
Methylphenidate .....	1724	II
Nabilone .....	7379	II
4-Anilino-N-Phenethyl-4-Piperidine (ANPP).	8333	II
Norfentanyl .....	8366	II
Cocaine .....	9041	II
Codeine .....	9050	II
Dihydrocodeine .....	9120	II
Oxycodone .....	9143	II
Hydromorphone .....	9150	II
Diphenoxylate .....	9170	II
Ecgonine .....	9180	II
Hydrocodone .....	9193	II
Levorphanol .....	9220	II
Meperidine .....	9230	II
Methadone .....	9250	II
Methadone intermediate .....	9254	II
Morphine .....	9300	II
Thebaine .....	9333	II
Opium tincture .....	9630	II
Oxymorphone .....	9652	II
Noroxymorphone .....	9668	II
Alfentanil .....	9737	II
Remifentanil .....	9739	II
Sufentanil .....	9740	II
Tapentadol .....	9780	II
Fentanyl .....	9801	II

The company plans to bulk manufacture the listed controlled substances for the internal use intermediates or for sale to its customers. In reference to drug codes 7360 (Marihuana), and 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture these drugs as synthetic. The company plans to bulk manufacture for either internal usage as intermediates or to sale to customers as Active Pharmaceutical Ingredients (API). No other activities for these drug codes are authorized for this registration.

**Brian S. Besser,**

*Acting Assistant Administrator.*

[FR Doc. 2022-00326 Filed 1-10-22; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA-944]

**Importer of Controlled Substances Application: Nexus Pharmaceuticals, Inc.**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Nexus Pharmaceuticals, Inc. has applied to be registered as an

importer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before February 10, 2022. Such persons may also file a written request for a hearing on the application on or before February 10, 2022.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on October 25, 2021, Nexus Pharmaceuticals, Inc., 10300 128th Avenue, Pleasant Prairie, Wisconsin 53158-7338, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Remifentanil .....	9739	I

The company plans to import the listed controlled substance for research and analytical testing purposes. Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. No other activity for this drug code is authorized for this registration.

**Brian S. Besser,**

*Acting Assistant Administrator.*

[FR Doc. 2022-00329 Filed 1-10-22; 8:45 am]

**BILLING CODE P**